Search Results

You are looking at 1 - 10 of 14 items for :

  • "pasireotide" x
Clear All
Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ and Albert Beckers

-generation somatostatin analogs in patients with AIP mutations, the role of other agents such as the GH receptor antagonist pegvisomant has been described in those with AIP mutations ( 14 ). Pasireotide is a newer somatostatin analog that is approved for use in

Open access

Solène Castellnou, Alexandre Vasiljevic, Véronique Lapras, Véronique Raverot, Eudeline Alix, Françoise Borson-Chazot, Emmanuel Jouanneau, Gérald Raverot and Hélène Lasolle

corticotroph tumor (cabergoline or pasireotide). Pasireotide, a second-generation somatostatin analog, acting on somatostatin receptor (SST) subtype 1,2,3 and 5, is the only approved pituitary-targeting drug for the treatment of Cushing’s disease ( 11 , 12

Open access

Hélène Lasolle, Amandine Ferriere, Alexandre Vasiljevic, Sandrine Eimer, Marie-Laure Nunes and Antoine Tabarin

. Pasireotide-LAR is a multireceptor-targeted somatostatin analog with superior clinical efficacy over octreotide-LAR ( 9 ) that can control GH and IGF-1 concentrations in patients resistant to 1gSRL ( 10 ). Consequently, it is approved for treatment of

Open access

Adrian F Daly, David A Cano, Eva Venegas-Moreno, Patrick Petrossians, Elena Dios, Emilie Castermans, Alvaro Flores-Martínez, Vincent Bours, Albert Beckers and Alfonso Soto-Moreno

adenomas were significantly more frequent in the low AIP-IHC group. Sparsely granulated adenomas have previously been shown to be associated with lower responses to octreotide/lanreotide and better responses to pasireotide and they predominate in AIP mut

Open access

Julie M Silverstein

Biopharmaceuticals Inc, Basking Ridge, NJ, USA), and pasireotide LAR are the currently available SSAs approved by the Food and Drug Administration for the treatment of patients with acromegaly (32, 33, 34, 35) . Approximately 50% of patients with acromegaly achieve

Open access

Maria Cristina De Martino, Richard A Feelders, Claudia Pivonello, Chiara Simeoli, Fortuna Papa, Annamaria Colao, Rosario Pivonello and Leo J Hofland

) was performed Everolimus induced a dose-dependent decrease of cell viability in the two adrenal cancer cell Pasireotide and mitotane Cell viability assay (WST-1) In the association of mitotane with everolimus, mitotane blocked everolimus

Open access

G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari and S Cannavò

) and second generation (pasireotide) somatostatin analogs (SSa), and the rationale of the use of radiolabeled-SSa for diagnostic imaging and PRRT ( 111 In-pentreotide, 177 Lu-DOTA, 90 Y-DOTA, 68 Ga-DOTA) ( 8 , 9 ). Herein we report on the

Open access

Sara Storvall, Helena Leijon, Eeva Ryhänen, Johanna Louhimo, Caj Haglund, Camilla Schalin-Jäntti and Johanna Arola

. Newer somatostatin analogs such as pasireotide and somatoprim have affinity for all receptor subtypes, although SST 4 to a lesser extent ( 20 ). Presumably, membranous expression stands as a prerequisite for successful treatment or for imaging using

Open access

K E Lines, R P Vas Nunes, M Frost, C J Yates, M Stevenson and R V Thakker

Research 2012 72 5060 – 5068 . ( doi:10.1158/0008-5472.CAN-12-1821 ) 24 Walls GV Stevenson M Soukup BS Lines KE Grossman AB Schmid HA Thakker RV. Pasireotide therapy of multiple endocrine neoplasia type 1-associated

Open access

Filippo Ceccato, Diego Cecchin, Michele Gregianin, Giacomo Ricci, Cristina Campi, Filippo Crimì, Marta Bergamo, Annibale Versari, Carmelo Lacognata, Federico Rea, Mattia Barbot and Carla Scaroni

adrenocorticotropin secretion . Journal of Endocrinological Investigation 2010 33 507 – 508 . ( ) 16 Verburg FA Anlauf M Mottaghy FM Karges W . Somatostatin receptor imaging-guided pasireotide therapy in medullary